Analyst consensus rating
Bicycle Therapeutics Analyst Rating: none
Direct answer
Bicycle Therapeutics's consensus rating is none.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $9.50.
Forecast evidence checked October 18, 2026.
Get free Bicycle Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $3.46
- Average price target
- $9.50
- High price target
- $14.00
- Low price target
- $5.00
- Low target gap
- +44.5%
- Target upside
- +174.6%
- High target gap
- +304.6%
- Target range width
- 260.1%
- Consensus rating
- none
- Analysts
- 6
- Evidence date
- October 18, 2026
- Valid through
- October 25, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Bicycle Therapeutics?
Bicycle Therapeutics has a verified none consensus. The same dataset has an average price target of $9.50.
How far are Bicycle Therapeutics's low and high targets from the recorded price?
The low target implies +44.5%, while the high target implies +304.6%.
How many analysts are included in Bicycle Therapeutics's consensus?
The verified consensus includes 6 analysts.
How is Bicycle Therapeutics's target upside or downside calculated?
The average target of $9.50 is divided by the recorded price of $3.46, then one is subtracted to produce +174.6%. This does not guarantee a future return.
When was Bicycle Therapeutics's analyst forecast verified?
The data was verified on 2026-10-18. The dataset is valid through 2026-10-25.